Abstract: Carvedilol is one of the most used cardiovascular drugs, highly metabolized by CYP450 2D6, 1A2, 2C9. Fluvoxamine, an antidepressant agent, is a moderate/potent inhibitor of these enzymes. There is the risk of drug-drug interaction when these two drugs are concomitantly administered. The aim of this study was to investigate the drug-drug interactions between carvedilol and fluvoxamine in vitro and in rats.
Introduction
 Carvedilol is a nonselective β-blocking agent, which is commonly used for the treatment of different cardiovascular diseases like hypertension, cardiac insufficiency, left ventricular dysfunction developed after a myocardial infarction  Carvedilol is metabolized via cytochrome P450, CYP2D6, CYP1A2 and CYP2C9 isoforms and by glucuronidation  Fluvoxamine is an antidepressant known to have inhibitory effect on cytochrome P450 (CYP2D6 and CYP1A2)
 The aim of this study was to investigate whether a pharmacokinetic interaction occurs between carvedilol and fluvoxamine in rats; the results may have an impact on the safety pharmacotherapy with carvedilol
Materials and methods
Subjects: 13 white male Crl:WI rats were included in the study, with a medium body-weight (b.w.) 330±20 g. The working protocol was reviewed and approved by the Ethics Committee of the University of Medicine and Pharmacy "Iuliu Hațieganu", Cluj-Napoca, Romania. 
In vivo

In vitro experimental design
 Rat liver microsomes were isolated by differential centrifugation. The microsomal incubations were performed at 37°C with 0.5 and 1 μM carvedilol and 0, 0.1, 0.75, 1.5 μM citalopram, with 0.25 mg microsomal protein/mL. The reaction was initiated by adding the NADPH regenerating system and was terminated by cooling on ice and adding cold acetonitrile at different time points (0.5, 1, 2, 3, 5, 7, 10, 15, 20, 25, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, 210 and 240 minutes) . Concentrations were thereby determined by HPLC-FLD assay. The incubations were completed in triplicate.
Pharmacokinetic analysis
 Non-compartmental pharmacokinetic analysis -PK parameters of carvedilol: C max (ng/mL), t max (hr), AUC (ng*hr/mL), k el (1/hr), t 1/2 (hr), Cl_F (mL/hr/kg), Vz_F (mL/kg).
Statistical analysis
 ANOVA was used for intergroup comparison, p< 0.05 for all analyses
Results and discussion 
